CADILA HEALTHCARE LTD. - 532321 - Intimation Under Regulation 30
Cadila Healthcare Ltd., enters into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine Zydus Cadila seeks DCGI nod for oral pill Desidustat to treat anaemia in kidney patients
Desidustat helps by reducing hepcidin, reducing inflammation, and better iron mobilisation CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus develops new treatment for patients suffering from Chronic Kidney Disease (CKD), submits first New Drug Application (NDA) to DCGI Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus develops new treatment for patients suffering from Chronic Kidney Disease (CKD), submits first New Drug Application (NDA) to DCGI CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcript of the Company's Q2 FY22 post results conference call held at 4:00 p.m. on October 29, 2021.
Zydus Cadila receives USFDA approval to market generic cancer drug in US
The company has received final approval from the US Food and Drug Administration (USFDA) to market Decitabine for Injection in the strength of 50 mg/vial single-dose vial. Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated November 20, 2021 titled 'Zydus Cadila receives final approval from USFDA for Decitabine Injection'.
Zydus Cadila gets USFDA nod for cancer drug with 180-days exclusivity
The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection CADILA HEALTHCARE LTD. - 532321 - Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 18, 2021 titled "Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA".